ONVO vs. MBOT, CYTH, INKT, NKGN, PLUR, ZIVO, SRZN, SABS, BCLI, and CRTX
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Microbot Medical (MBOT), Cyclo Therapeutics (CYTH), MiNK Therapeutics (INKT), NKGen Biotech (NKGN), Pluri (PLUR), ZIVO Bioscience (ZIVO), Surrozen (SRZN), SAB Biotherapeutics (SABS), Brainstorm Cell Therapeutics (BCLI), and Cortexyme (CRTX). These companies are all part of the "medical" sector.
Organovo (NASDAQ:ONVO) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
In the previous week, Organovo and Organovo both had 2 articles in the media. Organovo's average media sentiment score of 1.44 equaled Microbot Medical'saverage media sentiment score.
Organovo has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
Microbot Medical has a consensus target price of $7.00, indicating a potential upside of 586.27%. Given Microbot Medical's higher possible upside, analysts plainly believe Microbot Medical is more favorable than Organovo.
Microbot Medical received 151 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 70.67% of users gave Microbot Medical an outperform vote while only 49.62% of users gave Organovo an outperform vote.
Microbot Medical's return on equity of -149.24% beat Organovo's return on equity.
Microbot Medical has lower revenue, but higher earnings than Organovo. Microbot Medical is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
8.2% of Organovo shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 4.0% of Organovo shares are held by insiders. Comparatively, 10.6% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Microbot Medical beats Organovo on 11 of the 13 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
